SCHEMBL11964441

SCHEMBL11964441

Cc1ccc2nc([C@H](C)Nc3ncnc4c3ncn4C3CCCCO3)n(-c3ccccc3)c2c1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CYP2C19 P33261 1/20 0.45
▸ FLT3 P36888 4/20 0.40
▸ YTHDC1 Q96MU7 1/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ PI4KA P42356 1/20 0.37
▸ BLM P54132 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ADCY1 Q08828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11901800 0.92 NPC1 (0.51) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11901765 0.91 NPC1 (0.49) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11901315 0.90 NPC1 (0.51) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11901795 0.86 NPC1 (0.49) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11902087 0.85 NPC1 (0.48) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11901170 0.84 NPC1 (0.47) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11901167 0.84 NPC1 (0.47) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11964439 0.84 NPC1 (0.46) NPC1RAB9ASMN1; SMN2CYP2C19FLT3
SCHEMBL11901147 0.83 PIK3CD (0.53) NPC1RAB9ASMN1; SMN2CYP2C19YTHDC1
SCHEMBL11964435 0.83 NPC1 (0.47) NPC1RAB9ASMN1; SMN2CYP2C19FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 — — US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 NPC1 941/4885RAB9A 2082/4885SMN1; SMN2 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback